Motley Fool Asset Management LLC Buys 15,427 Shares of Penumbra, Inc. $PEN

Motley Fool Asset Management LLC boosted its position in Penumbra, Inc. (NYSE:PEN) by 169.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,556 shares of the company’s stock after acquiring an additional 15,427 shares during the period. Motley Fool Asset Management LLC owned 0.06% of Penumbra worth $7,635,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Penumbra by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock worth $238,365,000 after acquiring an additional 18,738 shares during the last quarter. Capital World Investors grew its holdings in Penumbra by 2.6% in the 4th quarter. Capital World Investors now owns 426,456 shares of the company’s stock worth $132,589,000 after acquiring an additional 10,724 shares during the last quarter. William Blair Investment Management LLC bought a new stake in Penumbra in the 4th quarter worth $107,567,000. AQR Capital Management LLC grew its holdings in Penumbra by 139.4% in the 2nd quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock worth $84,939,000 after acquiring an additional 192,734 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Penumbra by 6.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 318,154 shares of the company’s stock worth $98,917,000 after acquiring an additional 19,244 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Insider Activity at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director directly owned 8,719 shares of the company’s stock, valued at approximately $2,861,750.18. This trade represents a 1.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on PEN. Evercore reissued an “outperform” rating and issued a $335.00 price target on shares of Penumbra in a report on Thursday, May 7th. UBS Group reissued a “neutral” rating and issued a $374.00 price target on shares of Penumbra in a report on Thursday, February 26th. Citigroup cut their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Penumbra to a “hold” rating in a report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $361.33.

Penumbra Trading Up 0.3%

NYSE:PEN opened at $320.94 on Wednesday. The company has a 50-day moving average price of $326.26 and a 200-day moving average price of $326.91. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. The stock has a market cap of $12.62 billion, a price-to-earnings ratio of 73.95, a P/E/G ratio of 1.96 and a beta of 0.71.

Penumbra (NYSE:PEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The company had revenue of $374.76 million during the quarter, compared to analysts’ expectations of $370.47 million. During the same period in the prior year, the business posted $0.83 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. Equities analysts predict that Penumbra, Inc. will post 5.08 EPS for the current year.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.